News
Cetuximab Extends Survival In Advanced Non-Small Cell Lung Cancer
Robert Pirker
ROBERT PIRKER , Medical University of Vienna
Phase III study results have detected improvements in overall survival among patients with advanced non-small cell lung cancer treated with a monoclonal antibody targeted to the epidermal growth factor receptor: EGFR. Robert Pirker told the Turin congress he thinks is an emerging role for EGRF-targeted antibodies in lung cancer for patients who test positive for the epidermal growth factor receptor. He discussed the data with Peter Goodwin.
Phase III study results have detected improvements in overall survival among patients with advanced non-small cell lung cancer treated with a monoclonal antibody targeted to the epidermal growth factor receptor: EGFR. Robert Pirker told the Turin congress he thinks is an emerging role for EGRF-targeted antibodies in lung cancer for patients who test positive for the epidermal growth factor receptor. He discussed the data with Peter Goodwin.
Lung Cancer Screening: Wait for Prospective Study Findings!
Ugo Pastorino
UGO PASTORINO , Istituto Nazionale Tumori, Milan
Even the most sophisticated and powerful detection method for lung cancer detection, spiral CT, is still unproven in the context of mass screening for lung cancer. At the conference in Turin, Ugo Pastorino, urged delegates to wait for the findings of the large randomized studies of spiral CT now being conducted before deciding whether to use this technique. He discussed his group’s findings with Peter Goodwin.
Even the most sophisticated and powerful detection method for lung cancer detection, spiral CT, is still unproven in the context of mass screening for lung cancer. At the conference in Turin, Ugo Pastorino, urged delegates to wait for the findings of the large randomized studies of spiral CT now being conducted before deciding whether to use this technique. He discussed his group’s findings with Peter Goodwin.
Combinations and Targeted Agents: Better Survival in Mantle Cell Lymphoma
Martin Dreyling
Reporting From: 4th European Congress on Hematologic Malignancies, Paris 22-24 February, 2008
MARTIN DREYLING, University Hospital Grosshaden, Munich
Since the 1970s therapies for mantle cell lymphoma have greatly extended life, Martin Dreyling told conference delegates in Paris. He gave Peter Goodwin his latest data on combination therapy using the antibody, rituximab, and the emerging rôles of other targeted agents.
MARTIN DREYLING, University Hospital Grosshaden, Munich
Since the 1970s therapies for mantle cell lymphoma have greatly extended life, Martin Dreyling told conference delegates in Paris. He gave Peter Goodwin his latest data on combination therapy using the antibody, rituximab, and the emerging rôles of other targeted agents.
Chronic Lymphocytic Leukemia After Fludarabine Failure
John Gribben
Reporting From: 4th European Congress on Hematologic Malignancies, Paris 22-24 February, 2008
JOHN GRIBBEN, Bartholemews Hospital, London
New promise for treating chronic lymphocytic leukemia is arising from combining antibody therapies rituximab and alemtuzumab with new drugs such as lenalidomide alongside standard fludarabine therapy. At the Paris symposium John Gribben gave Peter Goodwin the latest details.
JOHN GRIBBEN, Bartholemews Hospital, London
New promise for treating chronic lymphocytic leukemia is arising from combining antibody therapies rituximab and alemtuzumab with new drugs such as lenalidomide alongside standard fludarabine therapy. At the Paris symposium John Gribben gave Peter Goodwin the latest details.
Liver Cancer: Risk Groups for Screening
Eugene Schiff
REFERENCE: General Session IV
EUGENE SCHIFF, University of Miami
Screening for Hepatitits C and B, and subsequent screening for cancer, can save millions of lives from hepatocellular carcinoma. Eugene Schiff told the Gastrointestinal Cancers Conference in Orlando which populations are most at risk. He discussed his data with Peter Goodwin.
EUGENE SCHIFF, University of Miami
Screening for Hepatitits C and B, and subsequent screening for cancer, can save millions of lives from hepatocellular carcinoma. Eugene Schiff told the Gastrointestinal Cancers Conference in Orlando which populations are most at risk. He discussed his data with Peter Goodwin.
How to Prevent Stomach and Esophageal Cancers?
William Blot
REFERENCE: General Session 1: Cancers of the Esophagus and Stomach
WILLIAM BLOT, Vanderbilt University, Nashville TN
Obesity emerged as a key cause of esophageal cancer from data presented by William Blot who told Peter Goodwin about the changing pattern of both esophageal and stomach cancer throughout the world, and about the likely ways of preventing them.
WILLIAM BLOT, Vanderbilt University, Nashville TN
Obesity emerged as a key cause of esophageal cancer from data presented by William Blot who told Peter Goodwin about the changing pattern of both esophageal and stomach cancer throughout the world, and about the likely ways of preventing them.
Early Breast Cancer Chemotherapy: Long Term Findings
Richard Peto
REFERENCE: Lancet 371:29-40; January 5, 2008
RICHARD PETO, Oxford University
The prospect of cutting breast cancer mortality in half throughout the world is held out by Richard Peto of the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). He talks with Peter Goodwin following the group’s most recent publication in The Lancet.
RICHARD PETO, Oxford University
The prospect of cutting breast cancer mortality in half throughout the world is held out by Richard Peto of the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). He talks with Peter Goodwin following the group’s most recent publication in The Lancet.
AACR In New Partnership For San Antonio Breast Cancer Symposium
Margaret Foti
MARGARET FOTI, American Association for Cancer Research, Philadelphia
The San Antonio Breast Cancer Symposium will, in the future, be presented jointly by the Cancer Therapy and Research Center at the University of Texas Health Science Center, Baylor College of Medicine, and the American Association for Cancer Research. Peter Goodwin found out more on this new collaboration from Margaret Foti, CEO of the American Association for Cancer Research in Philadelphia.
The San Antonio Breast Cancer Symposium will, in the future, be presented jointly by the Cancer Therapy and Research Center at the University of Texas Health Science Center, Baylor College of Medicine, and the American Association for Cancer Research. Peter Goodwin found out more on this new collaboration from Margaret Foti, CEO of the American Association for Cancer Research in Philadelphia.
Bivalirudin For Angioplasty: Expensive Heparin?»
Tony Gershlick, University of Leicester
Adnan Kastrati, Deutsches Herzzentrum, Munich
Using bivalirudin instead of heparin during angioplasty wasn't any better for preventing death, MI or urgent revascularisation in the 4,500-patient ISAR-REACT 3 study presented at the ACC annual meeting. Tony Gershlick and Adnan Kastrati discuss the study with Peter Goodwin and Sarah Freeman.Tony Gershlick, University of Leicester
Adnan Kastrati, Deutsches Herzzentrum, Munich
Tropical Health Research: London Scientist Honored»
Brian Greenwood, London School of Hygiene and Tropical Medicine
Brian Greenwood, of the London School of Hygiene and Tropical Medicine, has won the Hideyo Noguchi Africa Prize for his numerous achievements in tropical disease research. He talked withy Derek Thorne about his work, including the pivotal research proving that bed nets can help prevent malaria.Brian Greenwood, London School of Hygiene and Tropical Medicine
© 2008 Audio Medica - Medical Audio News Interviews & Podcasts. 
